Zoonotic tuberculosis: a complex issue of the Mycobacterium tuberculosis complex

Vitale, María

doi:10.1016/s2666-5247(20)30032-x

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The isolation of M. orygis from cattle and the identification of the same species in humans in India has raised concerns about the broad host spectrum of the pathogen. In light of reports regarding the low susceptibility of native Indian breeds for M. bovis infection as compared to the native European breeds, Vitale hypotheses that M. bovis might have become a pathogen of Bos taurus in Europe and the Americas, while M. orygis became a pathogen infecting Bos indicus in south Asia [ 2 , 24 ]. This is also supported by the fact that no M. bovis whole genome sequences have been deposited in the sequence read archive (SRA) registry from the South East Asian region so far.…”

Section: Need For Btb Control Policies In India- the Human Frontmentioning

confidence: 99%

Bovine tuberculosis in India: The need for One Health approach and the way forward

Ramanujam

Palaniyandi

2023

One Health

View full text Add to dashboard Cite

Section: Need For Btb Control Policies In India- the Human Frontmentioning

confidence: 99%

Bovine tuberculosis in India: The need for One Health approach and the way forward

Ramanujam

Palaniyandi

2023

One Health

View full text Add to dashboard Cite

“…Tuberculosis (TB) is a respiratory disease caused by Mycobacterium tuberculosis complex ( 1 ), a group of bacteria which primarily attacks the lungs along with other body parts such as the kidneys, spine, and brain. This airborne infectious disease can spread from person to person and it was the leading cause of death in the 1900's in Europe.…”

Section: Introductionmentioning

confidence: 99%

The BCG Vaccine for COVID-19: First Verdict and Future Directions

González-Pérez

Sánchez-Tarjuelo

Shor³

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Despite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world population. In this interim, the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the pandemic impact in some countries and the BCG vaccine offers significant advantages and flexibility in the way clinical vaccines are administered. BCG vaccination is a highly cost-effective intervention against tuberculosis (TB) and many low-and lower-middle-income countries would likely have the infrastructure, and health care personnel sufficiently familiar with the conventional TB vaccine to mount full-scale efforts to administer novel BCG-based vaccine for COVID-19. This suggests the potential for BCG to overcome future barriers to vaccine roll-out in the countries where health systems are fragile and where the effects of this new coronavirus could be catastrophic. Many studies have reported cross-protective effects of the BCG vaccine toward non-tuberculosis related diseases. Mechanistically, this cross-protective effect of the BCG vaccine can be explained, in part, by trained immunity, a recently discovered program of innate immune memory, which is characterized by non-permanent epigenetic reprogramming of macrophages that leads to increased inflammatory cytokine production and consequently potent immune responses. In this review, we summarize recent work highlighting the potential use of BCG for the treatment respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials. In situations where no other specific prophylactic tools are available, the BCG vaccine could be used as a potential adjuvant, to decrease sickness of SARS-CoV-2 infection and/or to mitigate the effects of concurrent respiratory infections.

show abstract

Tuberculosis in wild animals in India

Ramanujam,

Palaniyandi

2024

Vet Res Commun

View full text Add to dashboard Cite

Zoonotic tuberculosis: a complex issue of the Mycobacterium tuberculosis complex

Cited by 3 publications

References 10 publications

Bovine tuberculosis in India: The need for One Health approach and the way forward

Bovine tuberculosis in India: The need for One Health approach and the way forward

The BCG Vaccine for COVID-19: First Verdict and Future Directions

Tuberculosis in wild animals in India

Contact Info

Product

Resources

About